Rocuronium elective surgery — Competitive Intelligence Brief

Rocuronium elective surgery (Rocuronium elective surgery) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule

Target snapshot

Rocuronium elective surgery (Rocuronium elective surgery) — Diskapi Yildirim Beyazit Education and Research Hospital. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium elective surgery TARGET	Rocuronium elective surgery	Diskapi Yildirim Beyazit Education and Research Hospital	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Standard Duration Combination NRT	Standard Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy combination	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine polacrilex lozenge	Nicotine polacrilex lozenge	University of Maryland, Baltimore	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Naltrexone Tablet and Nicotine Patch	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class